The OMER chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OMER chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The OMER stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View OMER Detailed Price Forecast - CNN Money||View OMER Detailed Summary - Google Finance|
|View OMER Detailed Summary - Yahoo! Finance||View OMER Stock Research & Analysis - Zacks.com|
|View OMER Trends & Analysis - Trade-Ideas||View OMER Major Holders - Barrons|
|View OMER Call Transcripts - NASDAQ||View OMER Breaking News & Analysis - Seeking Alpha|
|View OMER Annual Report - CompanySpotlight.com||View OMER OTC Short Report - OTCShortReport.com|
|View OMER Fundamentals - TradeKing||View OMER SEC Filings - Bar Chart|
|View Historical Prices for OMER - The WSJ||View Performance/Total Return for OMER - Morningstar|
|View the Analyst Estimates for OMER - MarketWatch||View the Earnings History for OMER - CNBC|
|View the OMER Earnings - StockMarketWatch||View OMER Buy or Sell Recommendations - MacroAxis|
|View the OMER Bullish Patterns - American Bulls||View OMER Short Pain Metrics - ShortPainBot.com|
|View OMER Stock Mentions - StockTwits||View OMER Stock Mentions - PennyStockTweets|
|View OMER Stock Mentions - Twitter||View OMER Investment Forum News - Investor Hub|
|View OMER Stock Mentions - Yahoo! Message Board||View OMER Stock Mentions - Seeking Alpha|
|View Insider Transactions for OMER - SECform4.com||View Insider Transactions for OMER - Insider Cow|
|View OMER Major Holdings Summary - CNBC||View Insider Disclosure for OMER - OTC Markets|
|View Insider Transactions for OMER - Yahoo! Finance||View Institutional Holdings for OMER - NASDAQ|
|View OMER Stock Insight & Charts - FinViz.com||View OMER Investment Charts - StockCharts.com|
|View OMER Stock Overview & Charts - BarChart||View OMER User Generated Charts - Trading View|
FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Posted on Thursday April 26, 2018
Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patients who have persistent TMA despite modification of immunosuppressive therapy. This is the second breakthrough therapy drug designation for OMS721, which last year received the designation from FDA for the treatment of Immunoglobulin A (IgA) nephropathy.
Research Report Identifies T. Rowe Price Group, Omeros, Old Dominion Freight Line, Dillard's, BGC Partners, and Rexnord with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Thursday April 19, 2018
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
Posted on Thursday April 19, 2018
Omeros Corporation announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018.
Omeros Corporation today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery Congress in Washington, D.C., April 13-17, 2018.